Abstract:Hematopoietic stem cell transplantation (HSCT) can cure malignant and nonmalignant hematological disorders. From 1983 to 2022, Taiwan performed more than 10,000 HSCT transplants. The Taiwan Blood and Marrow Transplantation Registry collects clinical information to gather everyone's experience and promote the advances of HSCT in Taiwan to gather everyone's experience and promote advances of HSCT in Taiwan. Compared with matched sibling donors, transplants from matched unrelated donors exhibited a trend of superior survival. In Taiwan, transplant donors showed remarkable growth from unrelated (24.8%) and haploidentical (10.5%) donors. The number of older patients (17.4%; aged ≥61 years) who underwent transplantation has increased markedly. This review summarizes several significant developments in HSCT treatment in Taiwan. First, the use of Anti-thymocyte globulin (ATG) and intravenous busulfan regimens were important risk factors for predicting hepatic sinusoidal obstruction syndrome. Second, a new, machine learning-based risk prediction scoring system for posttransplantation lymphoproliferative disorder has identified five risk factors: aplastic anemia, partially mismatched related donors, fludarabine use, ATG use, and acute skin graft-versus-host disease. Third, although the incidence of idiopathic pneumonia syndrome was low (1.1%), its mortality rate was high (58.1%). Fourth, difficult-to-treat mantle cell and T-cell lymphomas treated with autologous HSCT during earlier remission had higher survival rates. Fifth, treatment of incurable multiple myeloma with autologous HSCT showed a median progression-free survival and overall survival of 46.5 and 70.4 months, respectively. Sixth, different haploidentical transplantation strategies were compared. Seventh, caution should be taken in administering allogeneic HSCT treatment in older patients with myeloid leukemia with a Charlson Comorbidity Index ≥3 because of a higher risk of nonrelapse mortality.

Improvement of Hematopoietic Stem Cell Transplantation in the Targeted Therapy Era

Haematopoietic stem-cell transplantation in China in the era of targeted therapies: current advances, challenges, and future directions.

[Advances in Nutritional Support for Children Undergoing Hematopoietic Stem Cell Transplantation].

Current status and prospects of hematopoietic stem cell transplantation in China

Progress in unrelated and haploidentical donor hematopoietic stem cell transplantation :improvement of transplantation model and the latest clinical efficacy

Allogeneic Hematopoietic Stem Cell Transplantation in China: Where We Are and Where to Go

Update of the “beijing Protocol” Haplo-Identical Hematopoietic Stem Cell Transplantation

Allo-Hematopoietic Stem Cell Transplant in China: 2014 Update.

Optimization of T-cell Replete Haploidentical Hematopoietic Stem Cell Transplantation: the Chinese Experience

Hematopoietic stem cell transplantation:everyone has a donor

Pediatric hematopoietic stem cell transplantation in China: Data and trends during 1998–2012

Establish the Hematopoietic Stem Cell Transplantation System with Chinese Characteristics

Current Status and Development of Hematopoietic Stem Cell Transplantation in China： a Report from Chinese Hematopoietic Stem Cell Transplantation Register Group

Hematopoietic Stem Cell Transplantation in China: Current Status and Prospects.

Everyone has a donor: contribution of the Chinese experience to global practice of haploidentical hematopoietic stem cell transplantation

Advances and current status of stem cell transplantation in treatment of hematological malignancies in China

Prospective of hematopoietic stem cell transplantation

Update on current research into haploidentical hematopoietic stem cell transplantation.

Recent advancements in hematopoietic stem cell transplantation in Taiwan

Hematopoietic stem cell transplantation for the treatment of hematological diseases

Haploidentical Hematopoietic Transplantation Without T-cell Depletion: Current Status and Future Perspectives.